• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Aldurazyme (Laronidase) Solution for Intravenous Infusion

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013

Summary View



Postmarketing Experience
In postmarketing experience with Aldurazyme…
  • Laryngeal edema
Additional adverse reactions…
  • Fatigue, edema peripheral